Mark J. Gergen
Executive Chairman · Poseida Therapeutics, Inc.
IndividualSelling only6 10b5-1 trades
- 2024
- Dec 11, 2024
- 2
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Mark J. Gergen's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- BAKER BROS. ADVISORS LP - $172.50M in KYMR purchases and sales in the last 12 months
- Keith S. Manchester - $154.47M in ROIV purchases and sales in the last 12 months
- QVT Financial LP - $147.38M in ROIV purchases and sales in the last 12 months
- Daniel Allen Gold - $147.38M in ROIV purchases and sales in the last 12 months
- ULSE Inc. - $146.25M in ULS purchases and sales in the last 12 months
- Michael Benkowitz - $135.23M in UTHR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mark J. Gergen?
Mark J. Gergen is a corporate insider, tracked as Executive Chairman of Poseida Therapeutics, Inc. (PSTX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Mark J. Gergen last file a Form 4?
The most recent primary Form 4 on record is dated 11 December 2024, one of 2 filings going back to 2024.
Has Mark J. Gergen been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($562K) across all tracked filings.
